ABT-493 coformulated with ABT-530 — Competitive Intelligence Brief

ABT-493 coformulated with ABT-530 (ABT-493 coformulated with ABT-530) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor. Area: Virology / Hepatology.

phase 3 Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor HCV NS3/4A protease and NS5A protein Virology / Hepatology Small molecule

Target snapshot

ABT-493 coformulated with ABT-530 (ABT-493 coformulated with ABT-530) — AbbVie. ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-493 coformulated with ABT-530 TARGET	ABT-493 coformulated with ABT-530	AbbVie	phase 3	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor	HCV NS3/4A protease and NS5A protein
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Grazoprevir/Elbasvir	Grazoprevir/Elbasvir	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor class)

1. AbbVie · 1 drug in this class